MD Hyperbaric

When a world-renowned orthopedic surgeon looks at his own patient roster and sees professional athletes and high-performance individuals struggling to access the same recovery technology used in elite sports medicine, he either accepts the gap or builds a solution. Dr. Martin O'Malley chose the latter. In 2021, Dr. O'Malley opened the first MD Hyperbaric center at 360 East 72nd Street in Manhattan, New York, specifically to give his orthopedic patients and professional athletes access to medical-grade hyperbaric oxygen therapy — a treatment modality with decades of clinical literature behind it but frustratingly limited availability in outpatient and community settings. Co-founded with board member Mark Wiseman and headquartered in West Orange, New Jersey, MD Hyperbaric began franchising in 2024 under the franchisor entity MDH Franchisor LLC, a wholly-owned subsidiary of parent company MD Hyperbaric Holding Inc. By May 2025, the system had grown to six operating locations, with projections pointing toward nearly 20 locations by end of 2025 and a stated target of 25 or more centers by end of 2026. The MD Hyperbaric franchise operates within the global hyperbaric oxygen therapy market, which was valued at USD 3.98 billion in 2025 and is projected to reach USD 6.71 billion by 2034, representing a compound annual growth rate of 5.96%. For franchise investors, this is not a saturated, mature category fighting for marginal share — it is an early-stage clinical services market experiencing structural expansion driven by aging demographics, chronic disease prevalence, and growing consumer demand for advanced recovery and wellness modalities. This analysis is produced independently by PeerSense.com and contains no promotional content provided by MD Hyperbaric or its affiliates.

The industry backdrop for the MD Hyperbaric franchise opportunity is defined by several powerful secular trends converging simultaneously. The global HBOT devices market, separately estimated at USD 3.41 billion in 2025, is projected to reach USD 5.53 billion by 2035 at a CAGR of 4.95%, while the more narrowly defined medical hyperbaric chambers segment is forecast to reach USD 1.4 billion by 2033 at a CAGR of 6.9%. North America leads global market share, capturing 32% of total HBOT revenue in 2025, with the North American market alone valued at approximately USD 197.66 million in 2022 and projected to reach USD 251.39 million by 2030. On the demand side, the wound healing segment held the largest market share in 2024, driven by rising incidences of diabetic foot ulcers and pressure ulcers in an aging population with escalating rates of chronic disease. Beyond wound care, consumer awareness of HBOT applications for neurological conditions, traumatic brain injury, PTSD, Long COVID, post-surgical recovery, and sports rehabilitation has created an entirely new class of demand that did not meaningfully exist in outpatient franchise settings even a decade ago. The competitive landscape in franchised medical HBOT is notably fragmented, with very few established franchise systems operating at scale, which creates meaningful white space for a medically credentialed, physician-founded brand positioning itself at the intersection of clinical medicine and proactive wellness. Technological advancements, including the deployment of FDA-cleared and ASME PVHO-1 approved chambers such as the OxyHealth Fortius420 used by MD Hyperbaric, are raising the bar for clinical credibility and differentiating medical-grade operators from the growing but less regulated soft-chamber wellness market. Investors evaluating franchise opportunities in health and wellness should understand that HBOT is not a consumer fad but a clinically validated modality with expanding FDA-recognized indications, positioning the entire category for durable long-term demand.

The MD Hyperbaric franchise cost structure reflects the clinical sophistication of the model and positions it as a mid-to-premium investment within the medical wellness franchise category. The initial franchise fee is $50,000, a figure confirmed by the most current available documentation, though an earlier Entrepreneur.com reference from December 2022 listed the fee at $75,000, suggesting the fee structure has been revised downward since the brand's early commercial phase. Total investment for opening an MD Hyperbaric franchise ranges from approximately $300,000 to $500,000 inclusive of equipment, build-out, and initial inventory, with a more granular breakdown revealing $50,000 for the franchise fee, $10,000 for buildout net of tenant improvement allowance, $20,000 for fit and finish, $40,000 for working capital, and $280,000 for two HBOT chambers at $140,000 each — a figure that reflects an exclusive franchise discount from the retail price of $180,000 per unit, representing $80,000 in aggregate equipment savings. This totals $400,000 in equity capital expenditure, with a flexible startup model also accommodating $240,000 in financed capital expenditure for operators who prefer to preserve liquidity. Alternative investment range estimates from FDD-sourced data include a range of $129,550 to $524,200 and a separate range of $208,635 to $338,076, reflecting the variance introduced by the brand's three-tier model formats. The ongoing royalty fee is 8% of gross sales, and the brand fund contribution is an additional 2% of gross sales, bringing total ongoing fees to 10% of revenue — a figure at the higher end of the medical franchise spectrum, though not atypical for clinically intensive concepts with centralized medical oversight. One source indicates a minimum net worth threshold of $750,000, which likely represents total financial capacity rather than liquid capital alone. MDH Franchisor LLC is a wholly-owned subsidiary of MD Hyperbaric Holding Inc., and investors should note that the FDD does not include financial statements for the parent company nor any guarantee of the franchisor's obligations by the parent — a structural consideration worth examining closely during legal due diligence.

The MD Hyperbaric franchise operating model is designed around what the company describes as franchise simplicity with clinical sophistication, and the day-to-day operational profile reflects that dual mandate. The company offers three distinct franchise formats: Start-Up locations that integrate HBOT directly into existing physician practices, Integration models that create dedicated branded spaces within existing medical offices, and Flagship locations that function as standalone community recovery centers typically housing four or more chambers. This three-tier structure allows franchisees to match capital deployment to available real estate and existing infrastructure, and it opens the MD Hyperbaric franchise opportunity to a broader pool of candidates than a single rigid format would permit. Staffing requirements are intentionally lean, with the company emphasizing low overhead as a core profitability driver, and each location is staffed by prequalified medical directors who operate under protocols written by the company's own medical leadership. The training program is structured across three defined levels: industry-standard certification for medical directors, MD Hyperbaric-specific operational training, and technology platform training covering CRM and HR tools. Pre-opening support encompasses site selection, real estate negotiations, architectural design, compliance management, equipment procurement, and staff training — essentially a turnkey development pipeline that reduces the operational burden on the franchisee during the critical pre-launch window. Post-opening support continues with ongoing marketing programs, operational reviews, compliance evaluations, lead generation assistance, and business-to-business outreach support. Dr. Martin O'Malley serves as Chief Medical Officer, providing centralized medical oversight across the network, and franchisees have access to an extensive research library and network-wide best practices. In February 2026, the appointment of Dr. Jason Sonners as Chief Clinical Officer and Dave Globig as Chief Strategy Officer further reinforced the clinical and operational infrastructure available to franchise operators.

Item 19 financial performance data is disclosed in the MD Hyperbaric Franchise Disclosure Document. Based on the 2024 Item 19 data included in the 2025 FDD, a single operating unit reported gross sales of $740,796.33, with EBITDA of $263,634.45 — representing an EBITDA margin of approximately 35.6% on reported gross revenue. These are striking figures for a single-unit performance representation, and they deserve careful contextual analysis before being used as investment projections. The FDD's Item 19 disclosure is based on one franchised outlet's actual performance, meaning the statistical base is extremely limited and prospective franchisees should request all supporting documentation and conduct their own franchise validation calls before drawing forward-looking conclusions. On the investment side, if the $400,000 equity capital expenditure figure is used as a baseline and the reported EBITDA of $263,634 is applied, the implied pre-tax payback period on equity invested is approximately 18 months — a compelling figure if replicable, but one that carries substantial uncertainty given the single-unit sample size. The franchisor's own financial statements for 2024 show a net loss of over $57,000 and a negative net worth, with revenue heavily weighted toward initial franchise fees rather than ongoing royalties, which reflects the financial profile of a very young franchisor still building out its royalty-generating base. This is not unusual for a system in its first full year of franchising, but it is a material data point for investors assessing the long-term support capacity of the franchisor entity. The MD Hyperbaric franchise revenue picture should be evaluated through the lens of a brand at the earliest stage of its franchise growth curve, where the disclosed financial performance data represents potential rather than proven system-wide results.

The MD Hyperbaric franchise growth trajectory is one of the most aggressive in the emerging medical wellness franchise sector. The company was founded in 2021, began franchising in 2024, and had signed 7 franchise agreements in its first year of franchising while operating only one franchised unit open as of the end of 2024. By May 2025, the total system had grown to six operating locations, with projections pointing toward close to 20 locations by year-end 2025. The November 2024 announcement of 7 new locations throughout New York — including the first three facilities in Westchester, Syracuse, and Long Island targeted to open in Q1 2025 — represents a coordinated cluster-expansion strategy that is consistent with the brand's physician-partnership model and reduces market development costs through geographic density. The 25-plus center target by end of 2026, supported by the February 2026 executive leadership additions, signals that the company is investing in organizational infrastructure ahead of the growth curve rather than reacting to it. CEO Chris Neal, CMO Dr. Martin O'Malley, newly appointed CCO Dr. Jason Sonners, and CSO Dave Globig represent a leadership team combining clinical credibility with franchise and strategy expertise. The competitive moat for MD Hyperbaric is constructed on several pillars: physician-founded clinical authority, the use of FDA-cleared OxyHealth Fortius420 ASME PVHO-1 approved chambers, centralized medical director oversight, and proprietary protocols developed under Dr. O'Malley's leadership — differentiators that are difficult for non-medical operators to replicate at speed. The brand's positioning at the intersection of traditional orthopedic and sports medicine and the broader proactive wellness market gives it access to multiple high-growth consumer segments simultaneously.

The ideal MD Hyperbaric franchise candidate occupies a fairly specific profile, and the company has been explicit about its target franchisee demographics. Physicians looking to integrate HBOT into existing practices represent the primary target, followed by healthcare-adjacent professionals with clinical operations experience, and entrepreneurs seeking a grounded investment in a medically validated category. The three-tier format structure means that a physician with an existing practice can enter at the Start-Up or Integration level with lower capital requirements, while an entrepreneur or investment group may pursue a Flagship standalone center with a four-or-more chamber configuration. The company's expansion focus is explicitly national, with stated priority on top-ten U.S. expansion markets, though the immediate geographic concentration in New York State reflects both the brand's Manhattan origins and its physician-partnership expansion model. The timeline from signing to opening will vary depending on format selected and the complexity of build-out, but the comprehensive pre-opening support system — including contractor coordination, architectural design management, and equipment procurement — is structured to streamline that process. The three-level training curriculum, from medical director certification through CRM and HR platform training, is designed to prepare operators for both clinical compliance and business performance. Prospective franchisees should note that the system is in a very early and unproven stage from a franchise management perspective, with limited track record in managing a multi-unit franchise network at the corporate level — a risk factor that warrants transparent discussion during the discovery process and thorough review of Item 21 financial statements.

The MD Hyperbaric franchise opportunity sits at the intersection of three powerful investment theses: the growth of medical-grade wellness services, the aging of the U.S. population and its expanding chronic disease burden, and the emergence of franchised clinical concepts that bring institutional-grade treatment protocols to community-level outpatient settings. With a global HBOT market projected to reach USD 6.71 billion by 2034, a North American segment growing steadily from USD 197.66 million in 2022, and a physician-founded brand that has moved from a single Manhattan clinic in 2021 to a six-unit multi-state system with 25-plus center ambitions by end of 2026, the MD Hyperbaric franchise represents a genuine early-mover opportunity in a category where franchise infrastructure is still being built rather than competed over. The disclosed EBITDA of $263,634.45 on gross sales of $740,796.33 from a single operating unit offers a directional signal, but no substitute for rigorous independent due diligence — especially given the franchisor's current negative net worth and early-stage organizational development. Investors should weigh the brand's clinical credibility and market timing advantages against the inherent risks of franchising with a system that had only one franchised unit open at the end of its first year of franchising. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools to help investors evaluate these dynamics with precision. Explore the complete MD Hyperbaric franchise profile on PeerSense to access the full suite of independent franchise intelligence data.